Research Areas
- Mechanisms of Cancer Drug Resistance
- Mechanisms of Breast Cancer Cell Fusion
Scientific Achievements
- Elucidated a Mechanism of Cancer Drug Resistance
- Identification of a Mechanism of Breast Cancer Cell Fusion
- PMCID: PMC10893907; PMCID: PMC9721091
- PMCID: PMC8705709; PMCID: PMC8076281
Funding
RCMI Funding:
- U54MD015929, Research Project “Cancer cell fusion; A mechanism driving breast tumor heterogeneity and metastasis”
Other funding obtained with RCMI support:
- NIH, 1R16GM153544-01A1
- NIH/NCI, R03 CA223099
- NSF Award IDs 2417643, 2142465
- HBCU Pier Plan for Nuclear Data G634F30
- AIM-AHEAD and NCATS Training Program Fellowship
- Society for Investigative Dermatology (SID) Freinkel Diversity Fellowship
Scientific Advance
Inhibition of insulin-like growth factor 2 mRNA-binding protein 1 sensitizes colorectal cancer cells to chemotherapeutics. Published in FASEB BioAdvance, Volume 4, Issue 12, pages 816-829. PMCIDPMC9721091.
This study examined the effects of IGF2BP1 inhibition in cancer drug resistance. Using a variety of colorectal cancer cell lines with different characteristics, we observed that the inhibition of IGF2BP1 potentiates the anti-growth and anti-proliferative effects of chemotherapy drugs. In addition, we found that IGF2BP1 inhibition was sufficient to decrease the resistance of some chemotherapy‐resistant cancer cells. Inhibition of IGF2BP1 also increases cancer cell death and reduces their ability to migrate. The mechanisms by which the inhibition of IGF2BP1 sensitizes cancer cells to chemotherapy drugs might involve the reduction of the expression of some members of the multidrug resistance gene family.
NIH/NIMHD U54MD015929; NIH/NCI R03 CA223099 ; CA191550; CA243167
